Clinical trials: HIV Coinfection
HIV Infections, Hepatitis C
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
HIV and hepatitis C virus (HCV) infection are diseases that share the same risk factors and routes of transmission. For this reason, many people infected with HIV are also infected with HCV.
- Trial name
- C_ASCENT (NCT02194998)
- Testing
- Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
HIV-1 and HSV-2 Coinfection, HIV Infections
Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon
The study proposed that both clinical and subclinical HSV reactivation is associated with increased HIV shedding from mucosal surfaces, which may increase the infectiousness of HIV-1/HSV-2 coinfected persons.
- Trial name
- NCT00209313
- Testing
- Acyclovir
- Where
- Cameroon
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Depression, HIV Infections
Trial of Citalopram for the Prevention of Depression
With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in people with HIV.
- Conditions
- Depression, HIV Infections, Hepatitis C
- Trial name
- PICCO (NCT00317746)
- Testing
- Citalopram
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Marina Klein
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human…
- Trial name
- VOYAGE-1 (NCT03222583)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 48 sites in China, Singapore and 1 more
- Volunteers
- 546 people
- Sponsor
- AbbVie
HIV Infections, Hepatitis B
Prospective Cohort of HIV/HBV-coinfected Patients in Europe
The overall aim of the project is to establish an international multi-cohort research platform of HIV/HBV-coinfected individuals treated with tenofovir to improve our understanding of the determinants of treatment outcomes.
- Conditions
- HIV Infections, Hepatitis B, Coinfection
- Trial name
- Euro-B (NCT04984772)
- Volunteers
- 1,107 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Human Immunodeficiency Virus, Hepatitis C, Chronic
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
This is an prospective open label pilot study conducted over 32 weeks. A total of 25 eligible participants who are infected with HCV and HIV will be recruited from 2 Canadian HIV Trials Network (CTN) sites (Ottawa Hospital…
- Trial name
- CTN289 (NCT02660905)
- Testing
- E/C/F/TAF;, Ledipasvir-Sofosbuvir
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Ottawa Hospital Research Institute
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Tuberculosis, HIV
Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection
We propose a first interaction study between efavirenz (EFV) and R20mg/Kg taking into consideration the absence of data about R induction at this dose.
- Trial name
- RIFAVIRENZ (NCT01986543)
- Testing
- drug administration
- Where
- Uganda
- Volunteers
- 105 people
- Sponsor
- ANRS, Emerging Infectious Diseases
MDR-TB, HIV
A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes
The researchers of this study are observing the treatment of multi-drug resistant Mycobacterium tuberculosis (MDR-TB) in South Africa. MDR-TB can not be treated with the usual TB drugs and needs to be treated with special drugs.
- Trial name
- NCT02129244
- Testing
- NCM-Plus
- Where
- 15 sites in South Africa
- Volunteers
- 2,844 people
- Sponsor
- Johns Hopkins University
Hepatitis B, HIV
Hep Mec Cohort in Zambia
Observational cohort of adults with acute and chronic hepatitis B infection in Zambia, with and without HIV coinfection. Participants join the study at the time of diagnosis and before or at the time when they are starting…
- Trial name
- Hep Mec (NCT07589985)
- Where
- 3 sites in Zambia
- Volunteers
- 390 people
- Sponsor
- University of Alabama at Birmingham
Human Immunodeficiency Virus (HIV), Hepatitis C, Chronic
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and Molecular Biology of The George Washington University Medical Center are carrying out a research study to determine why patients with…
- Trial name
- NCT01206933
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- George Washington University
HIV-infection/Aids, Human Herpesvirus 4 Infections
Inflammation and Co-Infections in D²EFT
i2-D²EFT substudy is an observational cohort nested within the parent D²EFT study (NCT03017872). D²EFT goal is to compare the standard of care second-line antiretroviral therapy in people living with HIV whose first-line non…
- Conditions
- HIV-infection/Aids, Human Herpesvirus 4 Infections, Cytomegalovirus Infections, Human Herpesvirus 8 Infection
- Trial name
- i2-D²EFT (NCT04183738)
- Testing
- NRTIs, Darunavir, Ritonavir
- Sponsor
- Kirby Institute
HIV, Hepatitis C
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
This study will evaluate the effectiveness of pioglitazone in reducing liver fat content in patients with HIV and hepatitis C virus (HCV) infections.
- Conditions
- HIV, Hepatitis C, Liver Disease, Fatty Liver
- Trial name
- NCT00742326
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)
The purpose of the study is to explore the treatment of patients with acute hepatitis C infection (infection acquired within the last 6 months) who are also infected with human immunodeficiency virus (HIV).
- Trial name
- CHAT (NCT02006745)
- Testing
- Ribavirin, Telaprevir
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St Stephens Aids Trust
Hepatitis C, HIV Coinfection
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)
This study will evaluate the effect of ledipasvir/sofosbuvir (LDV/SOF) treatment on the pharmacokinetics (PK) and renal safety of tenofovir in the form of tenofovir alafenamide (TAF).
- Trial name
- NCT03126370
- Testing
- TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Human Immunodeficiency Virus (HIV), Tuberculosis
Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub-Saharan Africa.
- Conditions
- Human Immunodeficiency Virus (HIV), Tuberculosis, Coinfection
- Trial name
- NCT03800394
- Testing
- Observational PK study
- Where
- Ghana
- Volunteers
- 52 people
- Sponsor
- University of Florida
Hepatitis C, Acute
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or…
- Trial name
- TARGET3D (NCT02634008)
- Testing
- Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin
- Where
- 11 sites in Australia, New Zealand and 1 more
- Volunteers
- 83 people
- Sponsor
- Kirby Institute
Chronic HIV Infection, HCV Coinfection
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
This study examines the impact of fosamprenavir as part of an ART on virological, immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected subjects.
- Trial name
- FOSTER-C (NCT01222611)
- Testing
- Fosamprenavir
- Where
- 6 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infection
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
Immunogenicity is reduced in immunocompromised patients. The aim of this prospective randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of anti-HAV vaccine in HIV-1 infected patients with CD4…
- Trial name
- HEPAVAC (NCT00190242)
- Testing
- group1, group2
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris